Bone marrow transplantation for nonmalignant diseases

被引:17
作者
Saba, N [1 ]
Flaig, T [1 ]
机构
[1] Univ Minnesota, Hennepin Cty Med Ctr, Div Hematol Oncol & Transplantat, Minneapolis, MN 55403 USA
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2002年 / 11卷 / 02期
关键词
D O I
10.1089/152581602753658565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone marrow transplantation (BMT) has emerged as a major therapeutic option for a number of nonmalignant disorders affecting the bone marrow and leading to clinical manifestations most likely affecting distant organs. Disorders such as autoimmune diseases, metabolic disorders, hemoglobinopathies, immunodeficiencies, and others have been the target of high-dose therapy and autologous or allogeneic bone marrow, stem cell, or cord blood transplantation. Successful results have been reported in a large number of these disorders. In most instances the goal of transplantation is to provide sufficient degree of marrow engraftment to allow long-term amelioration of disease phenotype. For many of these disorders, early diagnosis is crucial in achieving the desired results as transplantation becomes difficult when significant end-organ damage sets in. Major unsolved problems, including toxicity of conditioning regimens, graft-versus-host disease, and donor availability, need to be addressed. We attempt to provide a comprehensive review of BMT and discuss unique features of this modality for treatment of nonmalignant disorders.
引用
收藏
页码:377 / 387
页数:11
相关论文
共 106 条
  • [1] Abboud MR, 1996, BONE MARROW TRANSPL, V17, P405
  • [2] Amado RG, 2000, SEMIN ONCOL, V27, P82
  • [3] Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia
    Andreani, M
    Manna, M
    Lucarelli, G
    Tonucci, P
    Agostinelli, F
    Ripalti, M
    Rapa, S
    Talevi, N
    Galimberti, M
    Nesci, S
    [J]. BLOOD, 1996, 87 (08) : 3494 - 3499
  • [4] THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME
    ARUFFO, A
    FARRINGTON, M
    HOLLENBAUGH, D
    LI, X
    MILATOVICH, A
    NONOYAMA, S
    BAJORATH, J
    GROSMAIRE, LS
    STENKAMP, R
    NEUBAUER, M
    ROBERTS, RL
    NOELLE, RJ
    LEDBETTER, JA
    FRANCKE, U
    OCHS, HD
    [J]. CELL, 1993, 72 (02) : 291 - 300
  • [5] REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE
    BARTON, NW
    BRADY, RO
    DAMBROSIA, JM
    DIBISCEGLIE, AM
    DOPPELT, SH
    HILL, SC
    MANKIN, HJ
    MURRAY, GJ
    PARKER, RI
    ARGOFF, CE
    GREWAL, RP
    YU, KT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) : 1464 - 1470
  • [6] Bernaudin F, 1997, BONE MARROW TRANSPL, V19, P112
  • [7] BINKS M, 1999, BONE MARROW TRANSP S, V280
  • [8] BRINGHAM SJ, 2000, ANN MED, V32, P615
  • [9] Hematopoietic stem cell transplantation for systemic lupus erythematosus
    Brodsky, RA
    Petri, M
    Jones, RJ
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) : 377 - +
  • [10] BURT RK, 1995, BONE MARROW TRANSPL, V16, P1